A novel ruthenium (II)-derived organometallic compound, TQ-6, potently inhibits platelet aggregation: Ex vivo and in vivo studies

Pharmacology, Toxicology and Pharmaceutical Science

• Adenosine Triphosphate 33%
• Anticoagulant Agent 33%
• Antithrombocytic Agent 33%
• Artery Thrombosis 33%
• Bleeding 33%
• Cardiovascular Disease 33%
• Cyclic Nucleotide 33%
• Disease 33%
• Fibrinogen 33%
• Fluorescein Isothiocyanate 100%
• Hydroxyl Radical 33%
• Integrin 66%
• Mitogen Activated Protein Kinase 33%
• Mouse 33%
• Organometallic Compound 100%
• P-Selectin 33%
• Phospholipase 33%
• Protein Kinase C 33%
• Receptor Agonist 33%
• Thromboembolism 33%
• Triflavin 33%